Compare ITT & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITT | GH |
|---|---|---|
| Founded | 1920 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 14.1B |
| IPO Year | N/A | 2018 |
| Metric | ITT | GH |
|---|---|---|
| Price | $174.11 | $103.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 21 |
| Target Price | ★ $203.89 | $82.76 |
| AVG Volume (30 Days) | 1.1M | ★ 2.2M |
| Earning Date | 10-29-2025 | 10-29-2025 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | ★ 2.16 | N/A |
| EPS | ★ 5.99 | N/A |
| Revenue | ★ $3,813,500,000.00 | $902,569,000.00 |
| Revenue This Year | $7.91 | $34.72 |
| Revenue Next Year | $5.90 | $26.46 |
| P/E Ratio | $29.01 | ★ N/A |
| Revenue Growth | 8.01 | ★ 30.38 |
| 52 Week Low | $105.64 | $29.91 |
| 52 Week High | $197.07 | $112.43 |
| Indicator | ITT | GH |
|---|---|---|
| Relative Strength Index (RSI) | 42.34 | 58.38 |
| Support Level | $170.45 | $100.21 |
| Resistance Level | $176.49 | $109.59 |
| Average True Range (ATR) | 5.00 | 3.88 |
| MACD | -0.92 | -1.50 |
| Stochastic Oscillator | 37.72 | 29.47 |
ITT began its journey as International Telephone & Telegraph in 1920. Through decades of acquisitions in the mid-1900s, ITT went from manufacturing telephone switching equipment to operating hotels, car rentals, insurance agencies, and bread bakeries. In 1995, the firm split into three separate entities, one of which is the ITT in current operation. After a few more spinoffs in 2011, today ITT Inc. sells automotive, industrial, and aerospace products such as brake pads, seals, pumps, valves, connectors, and regulators. It has operations around the globe with notable exposures to North America, Europe, and Asia.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.